IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

dabrafenib capsules

dabrafenib capsules
for oral use Initial U.S. Approval: 2013

As specified in the prescribing information, dabrafenib capsules is indicated for the treatment of melanoma. TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma, BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma, Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Facts about dabrafenib capsules

Approval Date: 2013
Proprietary Name: TAFINLAR (dabrafenib) capsules
Active Ingredient(s): dabrafenib
FDA-approved use: melanoma
Dosage Form: Capsules: 50 mg, 75 mg
Medicine Approved By: US FDA
Manufacturer: Novartis Pharmaceuticals Corporation
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “dabrafenib capsules” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For dabrafenib capsules

Approved accessible "dabrafenib capsules"

Tafinlar (dabrafenib) capsules were initially approved in 2013 to treat patients with certain melanomas. In 2022, it was approved for use in combination with Mekinist  to treat patients aged six years and older who have specific genetically mutated solid tumors (a gene called BRAF V600E) whose disease has progressed and who have no other treatment options.

How can 1 go about obtaining dabrafenib capsules?

If dabrafenib capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

TAFINLAR (dabrafenib) capsules, for oral use Initial U.S. Approval: 2013


Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398